enGene Revenue and Competitors
Estimated Revenue & Valuation
- enGene's estimated annual revenue is currently $12.1M per year.
- enGene's estimated revenue per employee is $155,000
- enGene's total funding is $54M.
Employee Data
- enGene has 78 Employees.
- enGene grew their employee count by 24% last year.
enGene's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President and Chief Operating Officer | Reveal Email/Phone |
2 | VP, Head CMC | Reveal Email/Phone |
3 | VP, Head Regulatory Affairs | Reveal Email/Phone |
4 | VP, Head Clinical Development Operations | Reveal Email/Phone |
5 | Chief Medical Officer | Reveal Email/Phone |
6 | Co-Founder & Chief Technology Officer | Reveal Email/Phone |
7 | Associate Director, Preclinical Development | Reveal Email/Phone |
8 | CEO & Director | Reveal Email/Phone |
9 | Chief Scientific Officer | Reveal Email/Phone |
10 | Chief Financial Officer | Reveal Email/Phone |
enGene Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is enGene?
enGene Inc. is a biotechnology company developing a proprietary non-viral gene therapy platform for localized delivery of nucleic acid payloads to mucosal tissues. The dually derived chitosan (DDX) platform has a high-degree of payload flexibility including DNA and various forms of RNA (siRNA, shRNA, lncRNA etc.) with broad tissue and disease applications. In addition to developing EG-70 for BCG-unresponsive NMIBC, enGene enGene is developing unique genetic medicines for respiratory indications. The company is also evolving its technology to enable applications in several mucosal tissues such as the nasal and genital mucosa as well as the gastrointestinal tract among others. enGene is supported financially by top-tier institutional investors including Forbion Capital Partners, Fonds de Solidarité FTQ, Pharmstandard International S.A., Lumira Capital and Johnson & Johnson Development Corporation.
keywords:N/A
$54M
Total Funding
78
Number of Employees
$12.1M
Revenue (est)
24%
Employee Growth %
N/A
Valuation
N/A
Accelerator
enGene News
About enGene Inc. enGene Inc. is a clinical-stage biotechnology company developing non-viral gene therapies based on localized delivery of...
enGene Inc., a Montréal-based biotechnology enterprise developing an innovative platform technology for delivering genes to cells lining the gastrointestinal tract, announced today the closing of a $13.5 million Series B investment round led by Forbion Capital Partners, with participation of new ...
enGene Inc., a Montreal, Quebec, Canada-based pre-clinical stage biopharmaceutical company developing a platform technology for the delivery of nucleotides (DNA or RNA) to the gut, has held an initial closing of a $13.25m financing. The round was led by Lumira Capital (via its Merck Lumira Bios ...
Other Companies in St-Laurent
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $32.1M | 98 | 8% | N/A |
#2 | $26.2M | 107 | 18% | N/A |
#3 | $15M | 115 | 8% | N/A |
#4 | $26M | 163 | 21% | N/A |
#5 | $15M | 165 | 17% | N/A |